PDCD1 and neoplasm: Consistent with the results of syngeneic mouse CT26 tumor model, combined treatment of EOAI3402143 and trametinib significantly decreased PD-1 protein abundance and suppressed tumor development in KP mice, evidenced by reduced tumor sizes and areas (Supplementary Fig. 9h–k).